
Sign up to save your podcasts
Or
This week’s episode will be focusing on one of the 2025 plenary sessions: SERENA-6, Camizestrant, a novel selective estrogen receptor degrader (SERD) + CDK 4/6i for tx of emergent ESR1 during 1L endocrine-based therapy + ahead of progression in stage 4 HR+/Her-2 negative breast cancer.
We discuss the trial design, endpoints, results, safety concerns, and how it fits into current practice.
4.8
168168 ratings
This week’s episode will be focusing on one of the 2025 plenary sessions: SERENA-6, Camizestrant, a novel selective estrogen receptor degrader (SERD) + CDK 4/6i for tx of emergent ESR1 during 1L endocrine-based therapy + ahead of progression in stage 4 HR+/Her-2 negative breast cancer.
We discuss the trial design, endpoints, results, safety concerns, and how it fits into current practice.
325 Listeners
493 Listeners
58 Listeners
281 Listeners
3,332 Listeners
1,095 Listeners
192 Listeners
43 Listeners
519 Listeners
349 Listeners
248 Listeners
109 Listeners
56 Listeners
366 Listeners
39 Listeners